| __timestamp | Amicus Therapeutics, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 33472000 |
| Thursday, January 1, 2015 | 76943000 | 47368000 |
| Friday, January 1, 2016 | 104793000 | 66871000 |
| Sunday, January 1, 2017 | 149310000 | 50675000 |
| Monday, January 1, 2018 | 270902000 | 78821000 |
| Tuesday, January 1, 2019 | 286378000 | 91944000 |
| Wednesday, January 1, 2020 | 308443000 | 111234000 |
| Friday, January 1, 2021 | 272049000 | 207447000 |
| Saturday, January 1, 2022 | 276677000 | 267587000 |
| Sunday, January 1, 2023 | 152381000 | 303055000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and HUTCHMED (China) Limited have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Amicus Therapeutics increased its R&D expenses by over 220%, peaking in 2020. This surge underscores their aggressive pursuit of new therapies. However, a notable decline in 2023 suggests a strategic shift or potential financial constraints. In contrast, HUTCHMED's R&D spending grew steadily, with a remarkable 800% increase over the same period, culminating in 2023. This consistent growth reflects their expanding pipeline and commitment to long-term innovation.
These trends highlight the dynamic nature of biotech investments, where strategic R&D spending can significantly impact a company's market position and future prospects.
Comparing Innovation Spending: Amgen Inc. and Amicus Therapeutics, Inc.
Sanofi vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Bristol-Myers Squibb Company and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Bristol-Myers Squibb Company and HUTCHMED (China) Limited
R&D Insights: How Teva Pharmaceutical Industries Limited and HUTCHMED (China) Limited Allocate Funds
Incyte Corporation or HUTCHMED (China) Limited: Who Invests More in Innovation?
Halozyme Therapeutics, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
R&D Insights: How Lantheus Holdings, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited: Who Invests More in Innovation?
R&D Insights: How Amicus Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc. Allocate Funds
R&D Spending Showdown: Amicus Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for HUTCHMED (China) Limited and Viridian Therapeutics, Inc.